• Top
  • 0086-519-82860351
  • QR code

Top 10 Most Valuable R&D Projects-EvaluatePharma

Home    Top 10 Most Valuable R&D Projects-EvaluatePharma

Vertex's triple combination, VX-659/VX-445 + Tezacaftor+ Ivacaftor, remains the most valuable project in the pharmaceutical industry pipeline.

With Vertex Pharmaceuticals already dominating the cystic fibrosis space, its therapy combining ivacaftor (available as Kalydeco) and tezacaftor (available in combination with ivacaftor as Symdeko) with VX-445 or VX-659, another cystic fibrosis transmembrane regulator(CFTR) corrector, is looking to further reinforce the company's position.

The list is dominated by large-cap pharma companies, however, a couple of other projects from mid-cap companies join Vertex's triplet. Immunomedics is looking to put its stamp on the oncology market with its antibody-drug conjugate sacituzumab govitecan. Meanwhile the FDA has agreed to an accelerated approval pathway for Global Blood Therapeutics'oral therapy, voxelotor, for sickle cell disease.

AbbVie is pushing its own JAK1 inhibitor, upadacitinib, into the rheumatoid arthritis and ulcerative colitis markets and Eli Lilly, its novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist combination, LY3298176, into the crowded diabetes drug market. In contrast, Novartis seeks return on investment with Zolgensma’s launch into the spinal muscular atrophy space – Novartis gained the gene therapy (previously AVXS-101) when it acquired AveXis in May 2018. Novartis also eagerly awaits the approval of its wet age-related macular degeneration (AMD) project,brolucizumab; the FDA is set to decide later in 2019.

Two of Celgene’s acquired assets make it to the list: ozanimod, an immunomodulator in development for multiple sclerosis, ulcerative colitis and Crohn’s disease and Liso-cel, its CAR-T cell therapy. They originated from Receptos and Juno Therapeutics respectively,however these projects look likely to change hands again if Bristol-Myers Squibb closes its acquisition of Celgene.

Despite a wide spread of therapeutic areas represented in the top 10, oncology has the highest number of candidates. Daiichi Sankyo prepares for its first regulatory submission of its HER2-targeting antibody drug conjugate, DS-8201 (backed by a collaboration agreement with AstraZeneca) – and this joins Liso-cel and sacituzumab govitecan in the most valuable oncology projects.(Source: EvaluatePharma)